ADOCIA is a biopharmaceutical company engaged in regenerative medicine and developing innovative local delivery systems for recombinant therapeutic proteins.

The delivery technology developed by ADOCIA is based on the formulation of recombinant therapeutic proteins with proprietary polymers. The polymers are built from polysaccharides modified with natural amino-acids and have heparin-like properties. They bind proteins and increase their stability and activity.

ADOCIA was founded by Gérard Soula, who is the founder and former CEO of Flamel Technologies. He has a strong experience in management and a deep expertise in the field of drug formulation.